Maricann Group (CSE:MARI) will begin trading today on the Canadian Securities Exchange under the stock symbol MARI.
As quoted in the press release:

“We have been building a very strong foundation to all aspects of our business over the last four years,” said Ben Ward, CEO of Maricann. “Now, as a public company, we continue to build on that foundation in capitalizing on growth opportunities across the expanding cannabis industry.”


Maricann’s public listing follows a series of recent transactions and approvals. On April 18, 2017, the shareholders of Maricann Inc. (“Old Maricann”), a private company, approved its previously announced reverse takeover transaction of Danbel Ventures Inc. (“Danbel”), a public company. On April 20, 2017 the reverse takeover of Danbel by the shareholders of Old Maricann was completed and Danbel changed its name to “Maricann Group Inc.” Old Maricann became a wholly owned subsidiary of the Company. On April 21, 2107 Maricann received approval to list its shares for trading on the CSE.

“Countless people worked very hard to get Maricann to this point, with our employees, shareholders, board members, senior executives and a range of suppliers putting their faith in our growth strategy,” said Ben. “We are moving forward on the path to becoming one of the world’s leading vertically integrated cannabis companies.”

About Maricann

Maricann is a vertically integrated low cost greenhouse producer and distributor of marijuana for medical purposes. As one of approximately 43 companies with a federal licence to cultivate cannabis and one of approximately 30 independent licensed producers with a federal licence to process and distribute cannabis, Maricann services a patient base with more than 8,000 registered patients. Maricann is currently undertaking an expansion of the cultivation and support facilities to support existing and future patient growth.

Click here to read the full press release.

Source: finance.yahoo.com

Numinus and Multidisciplinary Association for Psychedelic Studies collaboration
will conduct follow-on Compassionate Access trial in real-world setting in Vancouver, Canada

Numinus Wellness Inc. (“Numinus” or the “Company”) (TSXV: NUMI), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today congratulates the Multidisciplinary Association for Psychedelic Studies (MAPS) and the MAPP1 trial study team for their announcement of results from the Phase 3 randomized clinical trial of MDMA-assisted therapy for the treatment of severe post-traumatic stress disorder (PTSD).

Keep reading... Show less

Combined Company Will Maintain Industry Leading Scale in Retail, Cultivation & Production

Footprint Provides National Scale with a Deep Regional Focus in Attractive Markets

Keep reading... Show less

Combined Company Will Maintain Industry Leading Scale in Retail, Cultivation & Production

Footprint Provides National Scale with a Deep Regional Focus in Attractive Markets

Keep reading... Show less

Combined Company Will Maintain Industry Leading Scale in Retail, Cultivation & Production

Footprint Provides National Scale with a Deep Regional Focus in Attractive Markets

Keep reading... Show less

4Front Ventures Corp. (CSE: FFNT) (OTCQX: FFNTF) (“4Front” or the “Company”), a national multi-state cannabis operator and retailer with a market advantage in mass-produced, low-cost quality branded cannabis products, today announced that its executive team will participate in the upcoming Canaccord Genuity Virtual Cannabis Conference, held on Tuesday, May 11, 2021 .

Keep reading... Show less